In Issue 44 (February 2017), we review why EXCEL and NOBLE had such different findings for left main PCI, the three-year outcomes of the ABSORB II trial, and other key stories from TCT 2016. We also profile Rebecca Hahn and explore the management of leaflet thickening after TAVI.
[pdfviewer width=”100%” height=”940px” beta=”true”]https://cardiovascularnews.com/wp-content/uploads/sites/14/2017/02/44-Cardiovascular-News-EU.pdf[/pdfviewer]
